1. Home
  2. UAN vs ABCL Comparison

UAN vs ABCL Comparison

Compare UAN & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CVR Partners LP

UAN

CVR Partners LP

HOLD

Current Price

$121.56

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$5.42

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UAN
ABCL
Founded
2007
2012
Country
United States
Canada
Employees
N/A
N/A
Industry
Agricultural Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
2008
2020

Fundamental Metrics

Financial Performance
Metric
UAN
ABCL
Price
$121.56
$5.42
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$8.40
AVG Volume (30 Days)
49.7K
8.5M
Earning Date
04-29-2026
05-11-2026
Dividend Yield
7.91%
N/A
EPS Growth
61.98
10.91
EPS
4.72
N/A
Revenue
$606,038,000.00
$75,128,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$21.85
P/E Ratio
$26.32
N/A
Revenue Growth
15.36
160.56
52 Week Low
$81.18
$1.98
52 Week High
$139.50
$6.52

Technical Indicators

Market Signals
Indicator
UAN
ABCL
Relative Strength Index (RSI) 42.25 66.96
Support Level $120.05 $5.34
Resistance Level $139.42 $5.63
Average True Range (ATR) 4.66 0.43
MACD -0.98 0.05
Stochastic Oscillator 10.32 87.28

Price Performance

Historical Comparison
UAN
ABCL

About UAN CVR Partners LP

CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: